A remarkably effective and safe product likely to qualify for FDA 505(b)2 fast-tracking and approval in a short period of time at a modest development cost. Its primary audience is a limited number of neurology & psychiatry specialists dedicated to treating a neurodegenerative illness.

Until now, the medical field has only had one FDA-approved product to help treat these patients.

Vig -001 is a convenient, cost-effective dosage form to address the critical compliance needs of patients, families and treating physicians requiring personalized care.

This product is specifically designed to employ new technology and services to better care for patients.

This product is listed on the World Health Organization’s List of Essential Medicines and is “A-rated” meaning “Effective and Safe” by International Neurology and Movement Disorder Society.

This new indication use is made possible by new technologies and services paired with a patient-friendly formulation.

Our Development and Management team is seeking a collegial partner(s) to bring this product to market with a single clinical trial.

We encourage you to connect with us to discover “What is Possible”

Please contact Paul.Duffy@Vigilantpharma.com to learn more about this exciting and innovative asset capable of transformative change for your company.